Thermo Fisher Scientific Inc ($TMO) Stock Forecast: Up 8.0% Today

What is Thermo Fisher Scientific Inc?

Thermo Fisher Scientific Inc. (TMO) is a leading company in the scientific research and diagnostics industry. Today, the stock experienced a strong bullish movement, rising by 5.14%.

Why is Thermo Fisher Scientific Inc going up?

TMO stock is up 8.0% on May 28, 2026 17:36

• Thermo Fisher's stock saw a significant increase of 5.14%, propelled by the company's strong Q1 2026 results that surpassed expectations, leading to a positive revision of their full-year EPS guidance.
• Investor confidence in Thermo Fisher's technological advancements was further reinforced with the introduction of new advanced mass spectrometers at a major conference.
• Despite the optimistic market movement, concerns arise regarding the potential impact on adjusted EPS from the sale of its microbiology business and the overall macroeconomic challenges facing the company. Monitoring Thermo Fisher's strategies to address these obstacles will be crucial for investors.

TMO Price Chart

TMO Technical Analysis

TMO News

Thermo Fisher Scientific Inc Stock (TMO) Moved Up by 5.14% on May 28: Drivers Behind the Movement

Thermo Fisher Scientific Inc. (TMO) saw a 5.14% stock increase on May 28, driven by strong Q1 2026 results that surpassed analyst expectations and an upward revision of full-year EPS guidance. The company's growth was further fueled by the launch of new advanced mass spectrometers for research and pharmaceutical development, institutional investor confidence, positive analyst sentiment, and strategic expansion into Sweden's life sciences sector. Despite the positive movement, the sale of its microbiology business is expected to be dilutive to adjusted EPS, and the company still faces macroeconomic headwinds.

https://www.tradingkey.com/news/market-movers/261934228-market-movers-tmo-20260528

Thermo Fisher Launches E-Gel Power Snap Lite System

Thermo Fisher Scientific has released the Invitrogen E-Gel Power Snap Lite Electrophoresis System, a new compact, all-in-one platform for nucleic acid verification. This system integrates gel electrophoresis and imaging, streamlining routine workflows by eliminating the need for separate equipment and manual gel preparation. It aims to reduce hands-on time and improve consistency for researchers, complementing their existing advanced analysis tools.

https://www.contractpharma.com/breaking-news/thermo-fisher-launches-e-gel-power-snap-lite-system/

IQVIA Holdings Jumps 5.7% Amid Sector-Wide Rally

IQVIA Holdings Inc. saw its stock surge by 5.7% to $175.00, driven by a broad sector-wide rally in the diagnostics and research industry. This movement, which saw several peers like Agilent Technologies and Thermo Fisher Scientific also post significant gains, indicates a shift in investor sentiment towards the entire sector rather than specific company news. Investors are advised to monitor whether this rally is sustainable and if any announcements from leading companies will provide further clarity.

https://news.alphastreet.com/iqvia-holdings-jumps-5-7-amid-sector-wide-rally/amp/

Thermo Fisher (TMO) Unveils Advanced Mass Spectrometers at Key Conference

Thermo Fisher Scientific (TMO) announced the display of its new mass spectrometers, the Orbitrap Tribrid Apex and Orbitrap Excedion, at the American Society for Mass Spectrometry Conference. These advanced instruments aim to enhance data production and decision-making in scientific fields like proteomics and biologics by integrating high-performance technology with AI-driven software. Despite a strong GF Score™ of 83 and solid profitability, insider selling activity of $8.1 million over the past three months presents a mixed outlook for investors.

https://www.gurufocus.com/news/8888651/thermo-fisher-tmo-unveils-advanced-mass-spectrometers-at-key-conference

Is Thermo Fisher Scientific Inc. (TMO) a Buy as RBC Restarts Coverage With Sector Perform Rating?

RBC Capital has restarted coverage of Thermo Fisher Scientific Inc. (TMO) with a Sector Perform rating and a $490 price objective, citing improving market conditions but concerns about long-term growth sustainability. Concurrently, Thermo Fisher Scientific launched a new bioanalytical and biomarker laboratory in Gothenburg, Sweden, to meet increasing demand for advanced drug development solutions and strengthen its global network. The company is a global leader in scientific services, though the article suggests that some AI stocks may offer higher returns in a shorter timeframe.

https://www.insidermonkey.com/blog/is-thermo-fisher-scientific-inc-tmo-a-buy-as-rbc-restarts-coverage-with-sector-perform-rating-1770052/

Trending Today

Chipotle Mexican Grill Inc. ($CMG) Stock Forecast: Down 5.0% Today

CME Group Inc. ($CME) Stock Forecast: Down 5.4% Today

TripAdvisor Inc. ($TRIP) Stock Forecast: Up 5.3% Today

Teleflex Incorporated ($TFX) Stock Forecast: Up 2.1% Today

Xerox Corporation ($XRX) Stock Forecast: Down 7.6% Today

Wix.com Ltd. ($WIX) Stock Forecast: Up 9.6% Today

Gartner Inc. ($IT) Stock Forecast: Up 5.8% Today

Credo Technology Group ($CRDO) Stock Forecast: Down 5.3% Today

BlackLine, Inc. ($BL) Stock Forecast: Up 5.2% Today

Equifax Inc. ($EFX) Stock Forecast: Up 5.1% Today

Thermo Fisher Scientific Inc Price History

29.00.2026 - TMO Stock was down 5.2%

• Thermo Fisher (TMO) experienced a bearish movement despite reporting better-than-expected Q4 CY2025 results, with revenue surpassing analyst estimates and strong performance in its Life Sciences Solutions segment.
• The stock might have faced downward pressure due to profit-taking by investors following the immediate stock increase post-earnings report.
• The overall market sentiment could have been influenced by broader market conditions or sector rotation, leading to the bearish movement in TMO's stock price today.
• It's possible that investors were expecting even stronger guidance or future outlook from the company, causing some disappointment and resulting in the bearish market movement.

23.03.2026 - TMO Stock was down 10.0%

• Thermo Fisher's stock experienced a bearish movement despite beating first-quarter earnings estimates, primarily due to concerns over modest organic growth and a cautious outlook.
• The company's reliance on acquisitions for revenue growth, with organic growth at only 1%, raised investor worries about sustainable future growth prospects.
• The CEO's optimistic comments about benefiting from domestic manufacturing efforts and strategic collaborations were overshadowed by the market's focus on underlying growth challenges and revenue outlook concerns.
• The bearish trend might have been further exacerbated by profit-taking behavior following the recent stock repurchases and dividend increase, as investors reevaluated the company's overall growth trajectory.

23.03.2026 - TMO Stock was down 11.0%

• Thermo Fisher Scientific reported strong first-quarter results with revenue and earnings growth, driven by acquisitions and new product launches.
• Despite beating earnings estimates, the stock experienced a bearish movement due to concerns over modest organic growth and a cautious full-year revenue outlook.
• Investors focused on the company's reliance on acquisitions for revenue increase and the slightly below-consensus full-year revenue guidance, leading to the stock decline.
• The market reaction suggests that while the company's financials are solid, concerns about future organic growth and demand are weighing on investor sentiment, resulting in the bearish movement of the stock.

23.03.2026 - TMO Stock was down 10.5%

• Thermo Fisher Scientific's stock saw a bearish trend due to weaker-than-expected organic growth, which raised concerns about demand despite exceeding revenue and EPS expectations.
• The market reacted negatively to the company's reliance on acquisitions for growth, with organic revenue growth at only 1%, indicating a preference for sustainable core business performance.
• Despite successful capital deployment, new product launches, and strategic partnerships, investors prioritized the quality of underlying business growth over the earnings beat, leading to the stock decline.
• The bearish movement highlights the market's emphasis on sustainable growth and operational excellence rather than short-term financial metrics, impacting Thermo Fisher's stock performance negatively.

02.00.2026 - TMO Stock was up 2.2%

• The global single-use bioprocessing products market is expected to witness substantial growth, with Thermo Fisher Scientific Inc. playing a significant role in the industry's advancement, contributing to the optimistic market trends.
• Noteworthy increases in stakes by Allspring Global Investments Holdings LLC and Ninety One UK Ltd in TMO reflect a growing confidence in the company's future, potentially influencing a rise in the stock's value.
• Despite recent significant insider sales, the company's impressive quarterly earnings report surpassing expectations, coupled with the initiation of a new stock buyback program and quarterly dividend declaration, have likely bolstered investor trust in TMO.
• The collective institutional interest and portfolio adjustments by different investment entities indicate a favorable outlook for TMO, aligning with the current bullish market movement.

18.11.2025 - TMO Stock was down 2.4%

• The decline in TMO stock may be linked to profit-taking by institutional investors actively trading the stock.
• Despite positive updates on strong quarterly earnings and a $5 billion share buyback program, concerns arose among investors due to insider selling by the CEO and COO, potentially contributing to the stock's downward trend.
• Weak performance by West Pharmaceutical Services (WST) in the healthcare sector could have also impacted investor sentiment towards TMO, as some may have shifted away from underperforming healthcare stocks.
• In sum, today's bearish movement in TMO stock seems influenced by profit-taking, insider selling concerns, and broader sector trends affecting investor outlook.

12.01.2026 - TMO Stock was down 5.2%

• Varma Mutual Pension Insurance Co and Cornerstone Investment Partners LLC increased their holdings in TMO, showing confidence in the company's future prospects.
• ING Groep NV and Atria Investments Inc reduced their stakes in TMO, possibly due to profit-taking or portfolio rebalancing.
• The initiation of a $5 billion stock repurchase plan by Thermo Fisher Scientific may have influenced market sentiment, signaling management's belief in the company's undervaluation.
• Despite the mixed institutional activity and insider sales, analysts maintain a "Moderate Buy" rating for TMO, with an average price target of $633.68, reflecting positive quarterly earnings and growth potential.

14.03.2026 - TMO Stock was up 5.0%

• Thermo Fisher Scientific's stock surged 3.6% today, indicating a bullish trend.
• The collaboration with HealthVerity to enhance real-world data capabilities shows the company's commitment to advancing clinical research and evidence generation.
• The undervaluation of TMO compared to its GF Value™ and the strong GF Score™ of 88 highlight positive performance metrics despite insider selling, signaling potential challenges ahead.
• The focus on precision medicine growth through collaborations like PRECISE-SG100K biobank positions TMO well for long-term success in the evolving healthcare landscape.

28.04.2026 - TMO Stock was up 8.0%

• Thermo Fisher's stock saw a significant increase of 5.14%, propelled by the company's strong Q1 2026 results that surpassed expectations, leading to a positive revision of their full-year EPS guidance.
• Investor confidence in Thermo Fisher's technological advancements was further reinforced with the introduction of new advanced mass spectrometers at a major conference.
• Despite the optimistic market movement, concerns arise regarding the potential impact on adjusted EPS from the sale of its microbiology business and the overall macroeconomic challenges facing the company. Monitoring Thermo Fisher's strategies to address these obstacles will be crucial for investors.

28.04.2026 - TMO Stock was up 5.5%

• The recent bullish movement in TMO's stock can be linked to its target of achieving a 7% organic revenue compound annual growth rate (CAGR) as disclosed at its recent Investor Day, indicating strong growth potential and investor support.
• While there are concerns about the sustainability of long-term growth, TMO's strategic actions, including the launch of a new bioanalytical and biomarker laboratory in Sweden, underscore its dedication to meeting market needs and strengthening its industry position.
• The announcement of a quarterly cash dividend of $0.47 per common share showcases TMO's financial stability and commitment to shareholders, fostering positive investor sentiment.
• Despite the allure of alternative opportunities in AI stocks for potentially higher short-term returns, TMO's focus on long-term growth and strategic investments positions it well for continued success in the life sciences sector.

28.04.2026 - TMO Stock was up 7.3%

• Thermo Fisher (TMO) showcased its cutting-edge mass spectrometers at a major conference, highlighting its commitment to advancing scientific research and decision-making processes.
• Despite insider selling activity, the company's solid profitability and ambitious 7% annual growth target signal confidence in its future prospects.
• RBC Capital's Sector Perform rating and price objective suggest a balanced view on TMO's performance, acknowledging market improvements while cautioning about long-term growth sustainability.
• The emphasis on meeting increased demand for advanced drug development solutions and strengthening global networks reflects TMO's strategic positioning for growth, despite suggestions of potentially higher returns in certain AI stocks.